Table I.
Clinical parameters of patients with LUAD from TCGA.
| Variables | Patients (n=500) | MST (days) | Crude HR (95% CI) | Log-rank P-value |
|---|---|---|---|---|
| Age (years)a | 0.386 | |||
| ≤65 | 215 | 1,499 | 1 | |
| >65 | 264 | 1,454 | 1.143 (0.845–1.546) | |
| Sex | 0.754 | |||
| Female | 270 | 1,454 | 1 | |
| Male | 230 | 1,528 | 1.048 (0.783–1.403) | |
| Tumor stageb | <0.0001 | |||
| Stage I | 268 | 2,620 | 1 | |
| Stage II | 119 | 1,209 | 2.473 (1.719–3.559) | |
| Stage III | 80 | 879 | 3.495 (2.383–5.126) | |
| Stage IV | 25 | 826 | 3.819 (2.201–6.629) | |
| Tumor stageb | <0.0001 | |||
| Stage I+II | 387 | 1,632 | 1 | |
| Stage III+IV | 105 | 826 | 2.585 (1.894–3.528) |
a
Information of age was unavailable for 21 patients
b
Information of tumor stage was unavailable for 8 patients. TCGA, The Cancer Genome Atlas; MST, median survival time; LUAD, lung adenocarcinoma; HR, hazard ratio; CI, confidence interval.